WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Alnylam Pharmaceuticals
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy
Alnylam Pharmaceuticals | September 22, 2022
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer. Both executives will report to Chief Executive Officer, Yvonne Greenstreet. “Attracting and retaining top talent is one of my top priorities, and I’m thril...
Labiotech.eu | January 28, 2020
A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....
FierceBiotech | January 27, 2020
Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...
FierceBiotech | January 21, 2020
LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...
Medical, Industry Outlook
Whitepaper
Video
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE